LBP Protein, Human (HEK293, His)

LBP proteins play a central role in the innate immune response by directly binding to the lipid A moiety of bacterial lipopolysaccharide (LPS). This interaction enhances CD14 affinity, promotes its binding to LPS, and promotes cytokine release in response to bacterial lipopolysaccharide. LBP Protein, Human (HEK293, His) is the recombinant human-derived LBP protein, expressed by HEK293 , with C-6*His labeled tag. The total length of LBP Protein, Human (HEK293, His) is 456 a.a., with molecular weight of 55-75 kDa.

LBP takes center stage in the innate immune response by directly engaging with the lipid A moiety of bacterial lipopolysaccharides (LPS), a pivotal glycolipid abundantly present in the outer membrane of Gram-negative bacteria. This interaction serves as a critical affinity enhancer for CD14, promoting its association with LPS and facilitating the subsequent release of cytokines in response to bacterial lipopolysaccharide. Notably, LBP, when bound to LPS, establishes interactions through its C-terminus with both soluble and membrane-bound CD14, underscoring its instrumental role in orchestrating key events in the innate immune system's defense against bacterial pathogens.

Measured by its ability to enhance LPS-stimulated IL-8 secretion by THP 1 human acute monocytic leukemia cells. The ED₅₀ for this effect is 0.4641-3.401 ng/ml, corresponding to a specific activity is > 2.940×10⁵ U/mg.

• 
  Measured by its ability to enhance LPS-stimulated IL-8 secretion by THP 1 human acute monocytic leukemia cells. The ED₅₀ for this effect is 0.8044 ng/ml, corresponding to a specific activity is 1.243×10⁶ U/mg.

Human

HEK293

C-6*His

P18428 (A26-V481)

3929  [NCBI]

ANPGLVARITDKGLQYAAQEGLLALQSELLRITLPDFTGDLRIPHVGRGRYEFHSLNIHSCELLHSALRPVPGQGLSLSISDSSIRVQGRWKVRKSFFKLQGSFDVSVKGISISVNLLLGSESSGRPTVTASSCSSDIADVEVDMSGDLGWLLNLFHNQIESKFQKVLESRICEMIQKSVSSDLQPYLQTLPVTTEIDSFADIDYSLVEAPRATAQMLEVMFKGEIFHRNHRSPVTLLAAVMSLPEEHNKMVYFAISDYVFNTASLVYHEEGYLNFSITDDMIPPDSNIRLTTKSFRPFVPRLARLYPNMNLELQGSVPSAPLLNFSPGNLSVDPYMEIDAFVLLPSSSKEPVFRLSVATNVSATLTFNTSKITGFLKPGKVKVELKESKVGLFNAELLEALLNYYILNTFYPKFNDKLAEGFPLPLLKRVQLYDLGLQIHKDFLFLGANVQYMRV

Approximately 55-75 kDa due to the glycosylation

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of 20 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, pH 8.0 or PBS, 1mM EDTA, pH 8.0, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.